Additional payment received to exercise option to expand number of targets.

No definition available.

Name:	nrix_AdditionalPaymentReceivedToExerciseOptionToExpandNumberOfTargets
Namespace Prefix:	nrix_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Additional Payments

+ References

No definition available.

+ Details

Name:	nrix_AdditionalPayments
Namespace Prefix:	nrix_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Collaboration agreement contract term.

+ References

No definition available.

+ Details

Name:	nrix_CollaborationAgreementContractTerm
Namespace Prefix:	nrix_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Collaboration Agreement Contract Term, Extension

+ References

No definition available.

+ Details

Name:	nrix_CollaborationAgreementContractTermExtension
Namespace Prefix:	nrix_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Collaboration Agreement Expiration Term

+ References

No definition available.

+ Details

Name:	nrix_CollaborationAgreementExpirationTerm
Namespace Prefix:	nrix_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Contract With Customer Liability Revenue Recognized Excluding Opening Balance

+ References

No definition available.

+ Details

Name:	nrix_ContractWithCustomerLiabilityRevenueRecognizedExcludingOpeningBalance
Namespace Prefix:	nrix_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Contractual extended research period.

+ References

No definition available.

+ Details

Name:	nrix_ContractualExtendedResearchPeriod
Namespace Prefix:	nrix_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Contractual initial research period.

+ References

No definition available.

+ Details

Name:	nrix_ContractualInitialResearchPeriod
Namespace Prefix:	nrix_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Number Of Additional Specified Drug Targets

+ References

No definition available.

+ Details

Name:	nrix_NumberOfAdditionalSpecifiedDrugTargets
Namespace Prefix:	nrix_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Number Of Drug Candidates

+ References

No definition available.

+ Details

Name:	nrix_NumberOfDrugCandidates
Namespace Prefix:	nrix_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Number Of Performance Obligations

+ References

No definition available.

+ Details

Name:	nrix_NumberOfPerformanceObligations
Namespace Prefix:	nrix_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Number Of Products Arising From Collaboration

+ References

No definition available.

+ Details

Name:	nrix_NumberOfProductsArisingFromCollaboration
Namespace Prefix:	nrix_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Number Of Specified Drug Targets

+ References

No definition available.

+ Details

Name:	nrix_NumberOfSpecifiedDrugTargets
Namespace Prefix:	nrix_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Proceeds From Collaboration Agreement, Clinical Milestone Payment

+ References

No definition available.

+ Details

Name:	nrix_ProceedsFromCollaborationAgreementClinicalMilestonePayment
Namespace Prefix:	nrix_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Proceeds From Collaboration Agreement, Extension Payment

+ References

No definition available.

+ Details

Name:	nrix_ProceedsFromCollaborationAgreementExtensionPayment
Namespace Prefix:	nrix_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Research milestones payments received.

+ References

No definition available.

+ Details

Name:	nrix_ResearchMilestonesPaymentsReceived
Namespace Prefix:	nrix_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Revenue, Remaining Performance Obligation, Variable Consideration Amount, Certain Sales Milestones

+ References

No definition available.

+ Details

Name:	nrix_RevenueRemainingPerformanceObligationVariableConsiderationAmountCertainSalesMilestones
Namespace Prefix:	nrix_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Revenue, Remaining Performance Obligation, Variable Consideration Amount, Regulatory Milestones

+ References

No definition available.

+ Details

Name:	nrix_RevenueRemainingPerformanceObligationVariableConsiderationAmountRegulatoryMilestones
Namespace Prefix:	nrix_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Revenue, Remaining Performance Obligation, Variable Consideration Amount, Research And Development Milestones

+ References

No definition available.

+ Details

Name:	nrix_RevenueRemainingPerformanceObligationVariableConsiderationAmountResearchAndDevelopmentMilestones
Namespace Prefix:	nrix_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Revenue, Remaining Performance Obligation, Variable Consideration Amount, Target Licensing And Reservation

+ References

No definition available.

+ Details

Name:	nrix_RevenueRemainingPerformanceObligationVariableConsiderationAmountTargetLicensingAndReservation
Namespace Prefix:	nrix_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Upfront payment.

+ References

No definition available.

+ Details

Name:	nrix_UpfrontPayment
Namespace Prefix:	nrix_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Upfront payment of additional fees.

+ References

No definition available.

+ Details

Name:	nrix_UpfrontPaymentOfAdditionalFees
Namespace Prefix:	nrix_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Variable consideration included in transaction price.

+ References

No definition available.

+ Details

Name:	nrix_VariableConsiderationIncludedInTransactionPrice
Namespace Prefix:	nrix_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-11

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479837/606-10-45-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479837/606-10-45-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-8

+ Details

Name:	us-gaap_ContractWithCustomerAssetNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-11

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479837/606-10-45-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-8

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479837/606-10-45-2

+ Details

Name:	us-gaap_ContractWithCustomerLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 8
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483467/210-10-45-8

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-11

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479837/606-10-45-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-8

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479837/606-10-45-2

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-8

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12A

+ Details

Name:	us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-7

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	srt_ProductOrServiceAxis=nrix_LicenseRevenueMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=nrix_GileadAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=nrix_SanofiAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=nrix_SanofiAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=nrix_PfizerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=nrix_PfizerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaboration Agreements (Details)	1 Months Ended									2 Months Ended	3 Months Ended			6 Months Ended		33 Months Ended
Collaboration Agreements (Details)	Jun. 30, 2025 USD ($)	Mar. 31, 2025 USD ($)	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023 USD ($) product performanceObligation	Apr. 30, 2023 USD ($)	Jul. 31, 2022	Jan. 31, 2021 USD ($) target performanceObligation	Jun. 30, 2019 USD ($) candidate target	Mar. 31, 2024	May 31, 2026 USD ($)	May 31, 2025 USD ($)	May 31, 2024 USD ($)	May 31, 2026 USD ($)	May 31, 2025 USD ($)	May 31, 2026 USD ($)	Nov. 30, 2025 USD ($)	Mar. 31, 2023 target	Dec. 31, 2019 target
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue											$ 9,043,000	$ 44,056,000		$ 15,295,000	$ 62,509,000
Deferred revenue, current											13,324,000			13,324,000		$ 13,324,000	$ 17,580,000
License revenue
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue											0	30,000,000		$ 0	30,000,000
Gilead Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Drug targets \| target									5									1
Collaboration agreement contract term									5 years					5 years
Term extension			2 years							2 years
Extension payment													$ 15,000,000.0
Number of drug candidates \| candidate									1
Upfront payment									$ 45,000,000.0
Upfront payment of additional fees									$ 3,000,000.0
Research milestones payments received														$ 47,000,000.0
Clinical milestone payment														5,000,000.0
Research and development milestone payments											508,500,000			508,500,000		508,500,000
Target licensing and reservation payments											60,000,000.0			60,000,000.0		60,000,000.0
Certain sales milestones payments											1,200,000,000			1,200,000,000		1,200,000,000
Expiration term									10 years
Variable consideration included in transaction price														47,000,000.0
Collaboration revenue recognized from opening contract liability											2,100,000	1,600,000		3,600,000	3,300,000
Recorded deferred revenue											200,000			200,000		200,000	3,800,000
Gilead Agreement \| License revenue
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue						$ 20,000,000.0
Gilead Agreement \| Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Number of drug candidates \| candidate									2
Additional payments											1,800,000,000			1,800,000,000		1,800,000,000
Sanofi Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Drug targets \| target								5											3
Term extension				2 years
Revenue											2,000,000.0	3,400,000		2,000,000.0	16,100,000
Upfront payment								$ 55,000,000.0
Expiration term								10 years
Variable consideration included in transaction price								$ 20,000,000.0
Recorded deferred revenue											0			$ 0		0	0
Additional payment received to exercise option to expand number of targets								$ 22,000,000.0
Additional drug targets \| target								2
Number of performance obligations \| performanceObligation								1
Contractual initial research period														4 years 3 months
Revenue recognized												3,100,000			9,100,000
Performance obligation satisfied												0			6,400,000
Sanofi Agreement \| Sanofi Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Research milestones payments received														$ 22,000,000.0
Research and development milestone payments											187,000,000.0			187,000,000.0		187,000,000.0
Certain sales milestones payments											500,000,000.0			500,000,000.0		500,000,000.0
Regulatory milestone payments											250,000,000.0			250,000,000.0		250,000,000.0
Sanofi Agreement \| License revenue
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue	$ 15,000,000.0	$ 15,000,000.0												30,000,000.0
Sanofi Agreement \| Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Extended research term							5 years 3 months
Sanofi Agreement \| Maximum \| Sanofi Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Additional payments											937,000,000.0			937,000,000.0		937,000,000.0
Sanofi Agreement \| Minimum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Extended research term							1 year
Pfizer
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue											5,000,000.0	$ 4,000,000.0		9,700,000	$ 8,000,000.0
Variable consideration included in transaction price					$ 15,000,000.0
Recorded deferred revenue											19,100,000			19,100,000		19,100,000	23,800,000
Number of performance obligations \| performanceObligation					1
Contractual initial research period					4 years
Products arising from collaboration \| product					2
Deferred revenue, current											13,100,000			13,100,000		13,100,000	13,800,000
Contract assets																	$ 5,000,000.0
Pfizer \| Pfizer
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment					$ 60,000,000.0
Research milestones payments received																15,000,000.0
Additional payments											3,400,000,000			3,400,000,000		3,400,000,000
Research and development milestone payments											621,000,000.0			621,000,000.0		621,000,000.0
Target licensing and reservation payments											19,500,000			19,500,000		19,500,000
Certain sales milestones payments											1,800,000,000			1,800,000,000		1,800,000,000
Regulatory milestone payments											$ 873,000,000.0			$ 873,000,000.0		$ 873,000,000.0
Pfizer \| Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contractual initial research period					6 years
Pfizer \| Minimum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contractual initial research period					4 years